Atea Pharmaceuticals, Inc.: cash and cash equivalents
Cash and cash equivalents for Atea Pharmaceuticals, Inc. Inspect selected reporting periods, original units and SEC filing links; download the financial history.
All Atea Pharmaceuticals, Inc. financial histories
What this measure means
Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.
Exact concept: us-gaap:CashAndCashEquivalentsAtCarryingValue. Each value is a balance at the reporting date, not a flow earned over a year. Different units remain separate; no currency conversion or interpolation is applied.
Coverage of this history
Selected reporting periods run from 2018-12-31 to 2025-12-31. The SEC response was captured on 2026-09-19.
Selected filing history
| Period start | Period end | Value | Unit | Filed | Source filing |
|---|---|---|---|---|---|
| At date | 2025-12-31 | 95,713,000 | USD | 2026-03-05 | 10-K · 0001193125-26-094159 |
| At date | 2024-12-31 | 64,696,000 | USD | 2026-03-05 | 10-K · 0001193125-26-094159 |
| At date | 2023-12-31 | 143,823,000 | USD | 2025-03-06 | 10-K · 0000950170-25-034808 |
| At date | 2022-12-31 | 188,460,000 | USD | 2024-02-28 | 10-K · 0000950170-24-022226 |
| At date | 2021-12-31 | 764,375,000 | USD | 2023-02-28 | 10-K · 0000950170-23-005186 |
| At date | 2020-12-31 | 850,117,000 | USD | 2023-02-28 | 10-K · 0000950170-23-005186 |
| At date | 2019-12-31 | 21,661,000 | USD | 2022-02-28 | 10-K · 0001564590-22-007672 |
| At date | 2018-12-31 | 34,492,000 | USD | 2021-03-30 | 10-K · 0001564590-21-016724 |
Related financial histories
- Atea Pharmaceuticals, Inc.: total assets
- Atea Pharmaceuticals, Inc.: total liabilities
- Atea Pharmaceuticals, Inc.: stockholders equity
- Atea Pharmaceuticals, Inc.: net income or loss
- Atea Pharmaceuticals, Inc.: operating cash flow
- Atea Pharmaceuticals, Inc.: capital expenditure payments
- Atea Pharmaceuticals, Inc.: financing cash flow
- Atea Pharmaceuticals, Inc.: investing cash flow
- Atea Pharmaceuticals, Inc.: retained earnings or deficit
- Atea Pharmaceuticals, Inc.: basic weighted-average shares
- Atea Pharmaceuticals, Inc.: diluted weighted-average shares
- Atea Pharmaceuticals, Inc.: basic earnings per share
- Atea Pharmaceuticals, Inc.: diluted earnings per share
- Atea Pharmaceuticals, Inc.: income tax expense or benefit
- Atea Pharmaceuticals, Inc.: net property, plant and equipment
- Atea Pharmaceuticals, Inc.: share-based compensation expense
- Atea Pharmaceuticals, Inc.: operating income or loss
- Atea Pharmaceuticals, Inc.: current assets
- Atea Pharmaceuticals, Inc.: current liabilities
- Atea Pharmaceuticals, Inc.: current accounts payable
- Atea Pharmaceuticals, Inc.: operating expenses
- Atea Pharmaceuticals, Inc.: research and development expense
Inspect the source
- Entity
- Atea Pharmaceuticals, Inc. / CIK 0001593899
- Captured
- 2026-09-19T11:19:25.614Z
- SEC response SHA-256
1478d5a15cae7d68529b05d31111a645d4d4c6ce2b18807594a9e3f28e816906
Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON
Latest-filed annual-report facts per unit and reporting period at capture time. Duration facts cover 300 to 400 days. This selection can include restatements and is not a point-in-time backtest dataset. Missing concepts are omitted, never zero-filled. Values retain original units and are not currency converted. Extended concepts require compatible unit shapes and at least three reporting ends with changing values within one unit. Constant or incompatible added histories are omitted.
Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.
Use this in research
A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.
These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.
Research methodology · Execution and cost assumptions · Check backtest overfitting
Build with the open-source tools
Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.
- Get an API key and run your first validation
- Connect the MCP server to your coding assistant
- Inspect the ALPHAC engine on GitHub
- Read the MCP server source and integration examples
Read the published dataset with Python
import json
from urllib.request import urlopen
with urlopen("https://canlicapital.com/company-data/0001593899.json") as response:
record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
print(concept["tag"], next(iter(concept["observations"])))